Related Experiment Video
Updated: Sep 19, 2025
Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
Published on: April 2, 2012
Adeno-associated virus vector modification based on directed evolution technology for gene therapy targeting head and
Yiyuan Zhu1, Wei Ji2, Qi Zhang3
1Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Introduction:
Adeno-associated virus (AAV) vectors are promising tools for cancer gene therapy, yet their clinical application in head and neck squamous cell carcinoma (HNSCC) is hindered by suboptimal transduction efficiency and off-target risks. Bioengineered AAV capsids require optimization to enhance tumor-specific targeting while minimizing systemic toxicity.
Methods:
We employed a directed evolution strategy combining DNA shuffling and site-directed mutagenesis to generate AAV variants. Five rounds of in vitro selection were performed using HNSCC cell lines (SCC-090, SCC-152, FaDu), followed by validation through in vitro transduction assays and in vivo studies in HNSCC xenograft mouse models. AAVzy9-3, a lead capsid variant, was further tested for α2δ1-targeted gene silencing efficacy.
Results:
This capsid demonstrated superior transduction efficiency in SCC-090, SCC-152 and FaDu cells when compared to the most efficient parental capsid. The validation of AAVzy9-3 targeting of HNSCC cells was validated through both in vitro and in vivo methods, employing a transplanted tumor mouse model. The results showed that AAVzy9-3 was more effective at infecting HNSCC cells than the wild type, while demonstrating reduced infectious potential toward other cells and organs. Additionally, the study used AAVzy9-3 to knockdown α2δ1 expression in a mouse model of HNSCC transplanted tumors, resulting in reduced tumor size.
Discussion:
The development of AAVzy9-3, a novel AAV variant with HNSCC-specific tumor tropism, addresses critical limitations of conventional AAVs. The in vivo antitumor activity validates its therapeutic potential for HNSCC.
Insights
Researchers engineered a new Adeno-associated virus (AAV) variant, AAVzy9-3, for head and neck squamous cell carcinoma (HNSCC) gene therapy. This optimized AAV shows improved tumor targeting and reduced toxicity, demonstrating potential for HNSCC treatment.
Area of Science:
- * Gene therapy and molecular virology.
- * Oncology and cancer research.
- * Biotechnology and bioengineering.
Background:
- * Adeno-associated virus (AAV) vectors are promising for cancer gene therapy.
- * Current AAV applications in head and neck squamous cell carcinoma (HNSCC) face challenges with transduction efficiency and off-target effects.
- * Bioengineered AAV capsids are needed for enhanced tumor specificity and reduced systemic toxicity.
Purpose of the Study:
- * To develop novel AAV variants with improved HNSCC targeting.
- * To evaluate the efficacy and safety of engineered AAV capsids for HNSCC gene therapy.
- * To assess the therapeutic potential of AAVzy9-3 for HNSCC treatment.
Main Methods:
- * Directed evolution strategy combining DNA shuffling and site-directed mutagenesis to generate AAV variants.
- * In vitro selection using HNSCC cell lines (SCC-090, SCC-152, FaDu) over five rounds.
- * In vitro transduction assays and in vivo studies in HNSCC xenograft mouse models to validate AAVzy9-3 efficacy and tropism.
Main Results:
- * AAVzy9-3 exhibited superior transduction efficiency in HNSCC cell lines compared to parental capsids.
- * In vitro and in vivo studies confirmed AAVzy9-3's enhanced targeting of HNSCC cells with reduced off-target infections.
- * AAVzy9-3 demonstrated antitumor activity by reducing tumor size in an HNSCC mouse model through α2δ1 gene silencing.
Conclusions:
- * AAVzy9-3 is a novel AAV variant with specific tropism for HNSCC.
- * This engineered AAV addresses limitations of conventional AAV vectors for HNSCC gene therapy.
- * AAVzy9-3 shows significant therapeutic potential for HNSCC treatment due to its in vivo antitumor activity.
